Digital biomarkers are objective, quantifiable physiological and behavioral measures collected from digital devices that serve as indicators of disease states or health outcomes. In Parkinson's Disease, digital biomarkers capture the complexity of motor and non-motor symptoms through continuous monitoring.
Digital biomarkers differ from traditional clinical biomarkers in several key ways:
| Biomarker | Description | Clinical Relevance |
|---|---|---|
| Tremor Amplitude | Maximum acceleration during tremor episodes | Disease severity |
| Tremor Frequency | Dominant frequency of tremor (typically 4-6 Hz in PD) | Differential diagnosis |
| Tremor Power | Total energy in tremor frequency band | Treatment response |
| Tremor Duty Cycle | Percentage of time with detectable tremor | ON/OFF state detection |
| Biomarker | Description | Clinical Relevance |
|---|---|---|
| Gait Velocity | Average walking speed | Disease progression |
| Stride Length | Average step length | Fall risk |
| Cadence | Steps per minute | Mobility status |
| Gait Variability | Coefficient of variation in stride time | Disease severity |
| Swing Time Asymmetry | Left-right swing time difference | Neurodegeneration |
| Turn Duration | Time to complete 180-degree turn | Mobility impairment |
| Freeze of Gait Episodes | Number/duration of freezing events | Advanced disease |
| Biomarker | Description | Clinical Relevance |
|---|---|---|
| Finger Tap Rate | Taps per second | Motor slowing |
| Inter-Tap Interval | Time between successive taps | Bradykinesia severity |
| Tap Accuracy | Distance from target | Movement planning |
| Tap Fatigue | Performance decline over time | Motor learning |
| Sequence Effect | Progressive slowing in sequences | Classic PD feature |
| Biomarker | Description | Clinical Relevance |
|---|---|---|
| Dyskinesia Amplitude | Magnitude of involuntary movements | Chorea/dyskinesia severity |
| Spectral Content | Frequency characteristics | Movement type classification |
| Duration | Time with dyskinesia | Medication correlation |
| Distribution | Body regions affected | Phenotype characterization |
Changes in speech are among the earliest signs of PD:
| Biomarker | Description | Clinical Relevance |
|---|---|---|
| Voice Amplitude | Volume (hypophonia) | Disease severity |
| Pitch Variability | Fundamental frequency variation | Bradykinesia |
| Speech Rate | Syllables/words per minute | Motor speech impairment |
| Articulation Clarity | Vowel/consonant accuracy | Dysarthria |
| Pause Patterns | Frequency/duration of pauses | Fluency |
| Tremor in Voice | Vocal tremor frequency | Tremor type |
Voice analysis typically uses smartphone microphones or dedicated voice recording apps. Studies show that voice changes can be detected years before clinical diagnosis.
| Biomarker | Description | Clinical Relevance |
|---|---|---|
| REM Sleep Behavior Disorder | Muscle activity during REM sleep | Prodromal PD indicator |
| Sleep Efficiency | Time asleep vs. in bed | Non-motor symptoms |
| Sleep Fragmentation | Number of awakenings | Disease burden |
| Movement During Sleep | Periodic limb movements | Sleep disruption |
| Sleep Timing | Circadian rhythm patterns | Dopaminergic function |
| Biomarker | Description | Clinical Relevance |
|---|---|---|
| Typing Patterns | Keystroke dynamics | Attention, processing speed |
| App Usage Patterns | Interaction timing | Executive function |
| Navigation Behavior | Wayfinding performance | Spatial cognition |
| Response Latency | Decision reaction times | Processing speed |
Digital phenotyping captures "digital traces" of behavior through smartphone sensors:
Smartphones provide rich data collection through built-in sensors:
| Platform | Integration | Features |
|---|---|---|
| Rune Labs StrivePD | Apple Watch | FDA-cleared tremor tracking |
| Hinge Health | Wearable sensors | Exercise therapy |
| Verily Study Watch | Custom wearable | Research-grade data |
| Michael J. Fox Foundation | mPower | Research app |
The FDA has cleared several digital biomarkers for PD:
Digital biomarkers enable:
Digital endpoints in PD trials: